Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
  • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0031—Rectum, anus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

• the present invention generally relates to the treatment of enteric neuropathies such as Hirschsprung disease (HSCR) and intestinal hypoganglionosis.
• enteric neuropathies such as Hirschsprung disease (HSCR) and intestinal hypoganglionosis.
• the enteric nervous system extends along the entire gastrointestinal tract to control bowel motility, blood flow and epithelial activity in response to sensory stimuli (1).
• Interconnected enteric ganglia containing neurons and glia develop from neural crest-derived progenitors that migrate through the intestine during prenatal development. Incomplete colonization of distal colon by ENS progenitors causes Hirschsprung disease (HSCR), a condition affecting 1 in 5000 newborns (2,3).
• HSCR distal colon without neural ganglia (i.e., aganglionic colon) remains tonically contracted and does not propagate contractions, causing functional intestinal obstruction.
• HSCR symptoms include refractory constipation with retention of stool and air, abdominal distension, growth failure, occasional vomiting, bowel inflammation (enterocolitis) and a risk of bacterial translocation into blood causing sepsis and premature death (2).
• HSCR is clinically subdivided into short-segment (S-HSCR) and long-segment forms (L- HSCR) (4).
• S-HSCR which occurs in >80% of cases, means the ENS is absent from rectum and sigmoid colon.
• L-HSCR means longer regions of distal bowel are aganglionic.
• HSCR etiology remains incompletely understood, but many genes influence HSCR risk (2).
• genetic risk variants may combine with non-genetic factors to prevent full bowel colonization by ENS progenitors (5). This non-Mendelian inheritance occurs because many proteins must work together for normal ENS development.
• hypoganglionosis also known as intestinal hypoganglionosis, is a disorder causing a reduced number of nerves in the intestinal wall.
• Intestinal hypoganglionosis can mimic HSCR; patients with both conditions may present with chronic constipation, intestinal obstruction, and enterocolitis (inflammation of the intestines).
• Patients with hypoganglionosis may also suffer from severe complications including fecaloma (hardening of the feces inside the colon), bleeding or perforation of the intestine, and breathing problems resulting from a distended colon.
• the exact cause of hypoganglionosis is often not known. In some cases, it is due to factors present at birth (congenital), while other times it is believed to be an acquired condition.
• the management of isolated hypoganglionosis generally involves surgery to remove the affected bowel segment.
• the present disclosure relates to the use of GDNF for the treatment of one or more pathological features of enteric neuropathies such as Hirschsprung disease.
• the present disclosure relates to the following items 1 to 90:
• a method for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy comprising administrating a pharmaceutical composition comprising an effective dose of a recombinant Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a pharmaceutically acceptable carrier into the distal colon of the subject.
• GDNF Glial cell line-Derived Neurotrophic Factor
• GDNF polypeptide comprises an amino acid sequence having at least 70% identity with amino acids 78-211 of SEQ ID NO:1.
• GDNF polypeptide comprises an amino acid sequence having at least 90% identity with amino acids 78-211 of SEQ ID NO:1.
• GDNF polypeptide comprises an amino acid sequence having at least 95% identity with amino acids 78-211 of SEQ ID NO:1.
• GDNF polypeptide comprises amino acids 78-211 of SEQ ID NO:1. 6.
• the effective dose of recombinant GDNF polypeptide administered to the human subject corresponds to a dose of about 5 pg to about 20 pg in a mouse pup.
• a pharmaceutical composition comprising a recombinant Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a pharmaceutically acceptable carrier for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy, wherein the composition is for administration into the distal colon of the subject.
• GDNF Glial cell line-Derived Neurotrophic Factor
• composition for use according to item 31, wherein the GDNF polypeptide comprises an amino acid sequence having at least 70% identity with amino acids 78- 211 of SEQ ID NO:1.
• composition for use according to item 32, wherein the GDNF polypeptide comprises an amino acid sequence having at least 90% identity with amino acids 78- 211 of SEQ ID NO:1.
• composition for use according to item 33 wherein the GDNF polypeptide comprises an amino acid sequence having at least 95% identity with amino acids 78- 211 of SEQ ID NO:1.
• composition for use according to item 34 wherein the GDNF polypeptide comprises amino acids 78-211 of SEQ ID NO:1.
• the pharmaceutical composition for use according to item 51 wherein the enteric neurogenesis comprises production of enteric neurons and enteric glial cells.
• composition for use according to item 51 or 52, wherein the production of enteric neurons and/or glial cells comprises proliferation of enteric neuron and/or enteric glia progenitors.
• composition for use according to any one of items 31 to 58, wherein the pharmaceutical composition is for administration into the rectum and/or the sigmoid colon.
• a pharmaceutical composition comprising a recombinant Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a pharmaceutically acceptable carrier for the manufacture of a medicament for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy, wherein the medicament is for administration into the distal colon of the subject.
• GDNF Glial cell line-Derived Neurotrophic Factor
• GDNF polypeptide comprises an amino acid sequence having at least 70% identity with amino acids 78-211 of SEQ ID NO:1.
• GDNF polypeptide comprises an amino acid sequence having at least 90% identity with amino acids 78-211 of SEQ ID NO:1.
• GDNF polypeptide comprises an amino acid sequence having at least 95% identity with amino acids 78-211 of SEQ ID NO:1.
• GDNF polypeptide comprises amino acids 78- 211 of SEQ ID NO:1.
• enteric neurogenesis comprises production of enteric neurons and/or enteric glial cells.
• enteric neurogenesis comprises production of enteric neurons and enteric glial cells.
• FIGs. 1A-H show the set-up of GDNF therapy parameters in Hol T9/rg mice.
• FIG. 1A-B Distribution of 10mI methylene blue enemas in the colon of P4 (FIG. 1 A) and P8 (FIG. 1 B) Hol T9/T 9 pups.
• FIG. 1C Impact of GDNF concentration on survival of HoG 9/T9 pups that received 10mI enemas once daily between P4-P8. Indicated amounts correspond to the total quantity of GDNF that was administered each day.
• FIG. 1D Impact of treatment time window (P4-P8 vs.
• FIG. 1F Impact of food consistency (regular chow vs gel diet) on survival of Hol Tg/T9 pups that received GDNF enemas (10pg in 10mI) on a daily basis between P4-P8.
• FIG. 1G Impact of coadministration of ascorbic acid (Vit.C; 100mM final concentration), serotonin (5-HT; 1 pg/mI final concentration) and Endothelin-3 (ET3; 1 pg/mI final concentration) on survival of Hol Tg/T9 pups that received GDNF enemas (10pg in 10mI) once daily between P4-P8.
• FIG. 1H Neuron density in the colon (expressed in % of surface area) and associated health status of P20 Hol Tg/T9 mice that received GDNF enemas (10pg in 10mI) on a daily basis between P4-P8.
• FIGs. 2A-E show that GDNF enemas rescue aganglionic megacolon in HSCR mouse models.
• FIGs. 2A-C Daily administration of GDNF enemas to Hol T9/rg (FIG. 2A), Ednrb s ⁇ l/S ⁇ ' (FIG. 2B) and TashT Tg/rg (FIG. 2C) mice between P4-P8 positively impacts both megacolon symptoms (i.e.
• FIG. 2D Whole-mount immunofluorescence staining of colonic muscle strips from P20 mice shows that the 5-day GDNF treatment induces myenteric ganglia containing HuC/D + neurons and Sox10 + glia in the otherwise aganglionic region of Hol Tg/T 9 mice.
• FIG. 1 Dashed outline marks area occupied by extrinsic nerve fibers.
• FIG. 1 Dashed outline marks area occupied by extrinsic nerve fibers.
• FIG. 1 Dashed outline marks area occupied by extrinsic nerve fibers.
• FIG. 1 Dashed outline marks area occupied by extrinsic nerve fibers.
• FIG. 1 Dashed outline marks area occupied by extrinsic nerve fibers.
• FIG. 3 shows an overview of myenteric plexus and submucosal plexuses in the distal colon of WT, untreated Hol Tg/T9 or GDNF-treated HoF 9/T9 mice at P20.
• Insets are zoomed- in views of GDNF-induced ganglia in dashed boxes.
• GDNF-treated mice received 10pg GDNF in 10pL enemas once daily from P4-P8. All images show a z-stack projection representative of observations made from 3 mice. Scale bar, 100pm (large panels) and 50pm (insets).
• FIGs. 4A-C show an analysis of myenteric ganglion size and neuronal density in the colon of P20 HoG 9/G9 and TashT Tg/J 9 mice that were treated or not with GDNF between P4-P8.
• FIG. 4A Analysis of myenteric ganglion size in Hol Tg/T9 mice.
• FIG. 4B Analysis of neuronal density in TashT Tg/rg mice. The average neuronal density is indicated for each colon sub-region (represented by cylinders) along the length of the colon.
• FIG. 5C Analysis of myenteric ganglion size in TashT Tg/Tg mice.
• FIGs. 5A-C show an analysis of EdU incorporation in myenteric and submucosal ganglia of the colon from P20 WT and GDNF-treated Hol Tg/T 9 mice that were administered EdU between P4-P8.
• FIG. 5A Example of EdU incorporation in a z-stack projection of submucosal neurons (arrowheads) and glia (arrows) in the distal colon. Dashed outline marks area occupied by a single ganglion. Scale bar, 50 pm.
• FIG. 5B Quantitative analysis of EdU incorporation in submucosal neurons (HuC/D+) and glia (SOX10 + ) in mid and distal colon.
• FIG. 5C Quantitative analysis of EdU incorporation in myenteric (left panel) and submucosal (right panel) neurons (HuC/D + ) and glia (SOX10 + ) in distal colon.
• GDNF-treated mice received 10 pg GDNF in 10 pL enemas once daily from P4-P8.
• FIGs. 6A-K show the phenotypic and functional characterization of the GDNF-induced ENS in P20 Hol Tg/Tg mice.
• FIG. 6A-B Immunofluorescence-based quantitative analysis of GDNF-induced myenteric ganglia from the distal colon of Hol Tg/Tg mice shows WT-like neuron (HuC/D + ) to glia (Sox10 + ) ratio (FIG. 6A), and proportion
• GDNF-induced myenteric ganglia not only shows the presence of nitrergic and cholinergic neurons but also other neuron subtypes expressing either tyrosine hydroxylase (TH), substance P (SubP), calretinin (CaIR), or vasoactive intestinal peptide (VIP). All images are single focal planes representative of observations made from 3 mice per subtype marker, with arrows pointing to examples of indicated neuron subtypes. Scale bar, 20 pm. (FIG.
• Beta- diversity comparisons (FIG. 6K) with 95% confidence interval ellipses are based on non-metric multidimensional scaling (NMDS) of Bray-Curtis dissimilarity of the relative abundance of operational taxonomic units among samples (P ⁇ 0.001 ; PERMANOVA).
• FIGs. 7A-B show the proportion of nitrergic and cholinergic myenteric neurons in the proximal and mid colon of WT, untreated Hol T9/Tg or GDNF-treated HoG 9/G9 mice at P20.
• FIG. 7A Qualitative analysis of the proportion of nitrergic (left panel) and cholinergic (right panel) neurons. Scale bar, 50 pm.
• FIG. 7A Qualitative analysis of the proportion of nitrergic (left panel) and cholinergic (right panel) neurons. Scale bar, 50 pm.
• GDNF-treated mice received 10 pg GDNF in 10 pL enemas once daily from P4-P8.
• FIGs. 8A-B show supporting information for in vivo and ex vivo analyses of motility in the distal colon of WT, untreated Hol T9/T 9 or GDNF-treated Hol T9/T 9 mice at P20.
• FIG. 8A Correlation between neuron density in distal colon and time for bead expulsion in GDNF-treated Hol T9/T9 mice at P20 (in support of FIG. 6D).
• FIG. 8B Examples of electric field-stimulated and drug-modulated patterns of longitudinal smooth muscle contraction-relaxation in an organ bath equipped with a force transducer (in support of FIG. 6E).
• EFS electric field stimulation
• FIGs. 9A-B show an analysis of smooth muscle thickness in the distal colon of WT, untreated Hol T9/T 9 or GDNF-treated Hol T9/T 9 mice at P20.
• FIG. 9A Representative H&E-stained cross-sections of different colon segments, with smooth muscle thickness indicated by red brackets. Scale bar, 150 pm.
• GDNF- treated mice received 10 pg GDNF in 10 pL enemas once daily from P4-P8.
• FIGs. 10A-I show that extrinsic Schwann cell precursors (SCPs) are a source of GDNF- induced neurons and glia in the otherwise aganglionic colon.
• FIG. 10A Western blot analysis of GDNF distribution in different sub-regions of the Gl tract from WT, HoF 9/T9 and GDNF-treated HOF 9/T9 mice at P8. Endogenous GDNF (eGDNF) is normally restricted to the ileum in all mice whereas recombinant GDNF (rGDNF) is exclusively detected in the distal colon of GDNF-treated HOF 9/T9 mice.
• eGDNF Endogenous GDNF
• rGDNF recombinant GDNF
• FIG. 10B-C Time-course analysis of the distribution of a 6xHis-tagged version of GDNF ( HiS GDNF) used for enema treatments of HoG 9/G9 mice between P4-P8.
• HiS GDNF 6xHis-tagged version of GDNF
• Anti-His and anti-RET double staining of the distal colon at 2-day intervals shows that both Hi sGDNF and RET accumulate in the submucosa during the treatment (FIG. 10B). Both are also detected in induced myenteric neurons close to extrinsic nerve fibers at P8 (FIG.
• FIG. 10C Representative images from 10-hour long time-lapse recordings of aganglionic colon tissues from HoG ⁇ Q4- RFP mice showing that SCP-like cells are dividing (arrows) and migrating (arrowheads) on extrinsic nerve fibers. Explants were prepared from P4 distal colons and pre-cultured for 72h with GDNF before live imaging on a confocal microscope in the continued presence of GDNF. Images are projections of 50 pm-thick z-stacks representative of observations made from 3 explants. Scale bar, 100pm. (FIGs.
• FIG. 10E-F Anti-SOX10 and anti-Ki67 double labeling demonstrates that exposure to GDNF for 96h markedly increases the rate of SCP proliferation in explants of distal colon prepared from P4 HoFa ⁇ a mice.
• Images in FIG. 10E are single focal planes representative of observations made from 3 explants. Scale bar, 50 pm.
• Each value in FIG. 10F corresponds to the average percentage of Ki67 + SCPs (i.e., (Ki67 + SOX10 + / SOX10 + ) x 100) calculated from a minimum of 3 fields of view per explant (**P ⁇ 0.01; two-tailed Student’s t- test). (FIGs.
• 10G-H Immunofluorescence analysis of myenteric ganglia in the distal colon of P20 HoFa ⁇ a-Dhh- Cre J s ,+ -,R26 YFPI+ mice that were administered GDNF enemas and EdU via intraperitoneal injections between P4-P8.
• Four categories of induced neuron are detected: 1 ) SCP-derived (Dhh+ lineage) and EdU-positive (filled grey arrowhead); 2) SCP-derived and EdU-negative (empty grey arrowhead); 3) unknown origin and EdU-positive (filled white arrowhead); 4) unknown origin and EdU-negative (empty white arrowhead).
• Images in FIG. 10G are single focal planes representative of observations made from 3 mice.
• FIG. 10H The relative proportions of the four categories of induced neurons per ganglion plotted in FIG. 10H corresponds to the averages calculated from a minimum of 3 fields of view per mouse. Dashed outlines mark area occupied by either an extrinsic nerve fiber (FIG. 10E), or an extrinsic nerve fiber and an adjacent single ganglion (FIGs. 10C and G).
• FIG. 101 Schwann cells in the aganglionic distal colon of HoFa ⁇ a mice express neural cell adhesion molecule (NCAM) but not RET. Immunofluorescence analysis of NCAM and RET expression in extrinsic nerve fibers (delineated by dashed lines) from the distal colon of untreated HoFa ⁇ a mice at P20.
• NCAM neural cell adhesion molecule
• NCAM but not RET is expressed in SOX10 + Schwann cells and putative enteric glia/ENS progenitors (arrows).
• DAPI 4',6-diamidino-2-phenylindole.
• the displayed images are single focal planes representative of observations made from 3 mice. Scale bar, 50 pm.
• FIG. 11 shows an analysis of GDNF distribution in multiple tissues of GDNF-treated HoFa ⁇ a mice at P20.
• the displayed blots are representative of observations made from 3 mice.
• FIG. 12 shows a time-course analysis of HI S GDNF distribution and RET expression in colonic smooth muscles of P4-P8 HoFa ⁇ a mice treated with HI S GDNF.
• FIGs. 13A-D show an analysis of SCP-derived neurogenesis in myenteric and submucosal ganglia of Dhh-Cre Tg,+ ⁇ R26 YPP,+ and Hol Tg/Tg ⁇ Dhh-Cre lal+ ; R26 YFP,+ mice at P20.
• FIG. 13A Analysis of myenteric neurons (HuC/D + ) and YFP expression in the proximal colon of Dhh- Cre Ta,+ R26 YFP,+ (Ctl) and Hol Tg/Tg Dhh-Cre Ta,+ ; R26 YFP,+ (Hol rg/Tg ) mice. Yellow arrowheads point to SCP-derived neurons.
• FIG. 13C Analysis of submucosal neurons (HuC/D + ) and YFP expression in the distal colon of Hol Tg/Tg Dhh-Cre Jal+ ; R26 YFPI+ ( Hol Tg/Tg ) mice that were treated with GDNF between P4-P8. Neurons of either SCP (grey arrowhead) or unknown (white arrowhead) origin are detected.
• FIG. 13D Analysis of RET-expressing myenteric neurons (HuC/D + ) and YFP expression in the distal colon of Hol Tg/rg -,Dhh- Cre Jal+
• R26 YFPI+ Hol Tg/Tg
• RET is expressed in a subset of neurons, regardless of SCP (RET+, filled grey arrowhead; RET-, empty grey arrowhead) or non-SCP (white arrowhead) origin. All displayed images are z-stack projections representative of observations made from 3 mice. Scale bar, 50 pm. Dashed outline marks area occupied by a single ganglion.
• FIGs. 14A-H show the ex vivo preclinical testing of GDNF therapy on explants of aganglionic colon from Hol Tg/rg mice and human HSCR patients.
• FIGs. 14A-C Immunofluorescence-based analysis of explants prepared from the distal colon of P4 Hol Tg/Tg mice, and cultured for 96h in presence of GDNF and EdU (+GDNF) or EdU alone (ctl). New HuC/D + neurons can be induced by GDNF under these ex vivo culture conditions but the total number of neurons per explant is variable (FIG. 14A), these neurons only formed very small ganglia, if any (FIG.
• FIG. 14B Immunofluorescence- based analysis of explants prepared from samples of aganglionic colon resected from human HSCR patients, and cultured for 96h in presence of GDNF and EdU (+GDNF) or EdU alone (ctl).
• FIGs. 14D-E HuC/D + neurons
• FIG. 14F HuC/D + neurons
• FIG. 14H Extended culture in presence of GDNF for a total of 7 days allowed the detection of neurons in human explants from patients >3 months of age at the time of surgery, including some that incorporated EdU (arrowhead).
• FIGs. 15A-B show an analysis of neurogenesis and SCP proliferation in distal colon explants prepared from P4 Hol T9/T9 mice and cultured in presence or absence of GDNF for 96h.
• the displayed images are single focal planes representative of observations made from 7 mice. Scale bar, 50 pm. Dashed outline marks area occupied by extrinsic nerve fibers.
• FIG. 16 shows a marker analysis of GDNF-induced neurons in sigmoid colon explants prepared from HSCR patients and cultured in presence of GDNF for 96h.
• Immunofluorescence analysis showing that human GDNF-induced neurons are closely associated with extrinsic nerves and express bIII-T ubulin (TuJ1), RET, PGP9.5 and PHOX2B (in support of FIG. 14F). Arrowheads point to round/ovoid nuclei of PGP9.5 + neurons.
• the displayed images are single focal planes representative of observations made from 3 human samples. Scale bar, 100 pm (upper panels), 50 pm (middle panels) and 25 pm (lower panels).
• FIG. 17A shows the amino acid sequence of human GDNF isoform 1 (UniProtKB accession No. P39905, SEQ ID NO:1), with the sequence corresponding to the signal peptide underlined (residues 1-19), the sequence corresponding to the propeptide italicized (residues 20- 75) and the sequence corresponding to the mature polypeptide in bold (residues 78-211).
• FIGs. 17B-C show the nucleotide sequence of the cDNA encoding human GDNF isoform 1 (RefSeq accession No. NMJD00514.4, SEQ ID NO:2), with the sequence encoding the signal peptide underlined (nucleotides 562-618), the sequence encoding the propeptide italicized (nucleotides 619-786) and the sequence encoding the mature polypeptide in bold (nucleotides 793-1194).
• the term “about” has its ordinary meaning.
• the term “about” is used to indicate that a value includes an inherent variation of error for the device or the method being employed to determine the value, or encompass values close to the recited values, for example within 10% of the recited values (or range of values).
• GDNF can stimulate neurogenesis in cultured explants of aganglionic colon from human HSCR patients.
• GDNF appeared as a primary candidate for postnatal reactivation of ENS progenitors in the aganglionic zone notably because of its ability to stimulate migration and proliferation of Schwann cells in a RET-independent but GFRcd- dependent manner through its alternative receptor neural cell adhesion molecule (NCAM).
• recombinant GDNF administered in the colon may be used for the treatment for enteric neuropathies (e.g., ENS defects such as HSCR) i.e. for improving one or more of the pathological features of enteric neuropathies, in human patients.
• enteric neuropathies e.g., ENS defects such as HSCR
• the present disclosure provides a method for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy (e.g., Hirschsprung disease (HSCR) or intestinal hypoganglionosis), the method comprising administrating a pharmaceutical composition comprising an effective dose of a Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a pharmaceutically acceptable carrier into the distal colon of the subject.
• a pharmaceutical composition comprising an effective dose of a Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a pharmaceutically acceptable carrier into the distal colon of the subject.
• GDNF Glial cell line-Derived Neurotrophic Factor
• the present disclosure also provides a method for restoring distal colon motility and/or epithelial barrier in a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), the method comprising administrating a pharmaceutical composition comprising an effective dose of a GDNF polypeptide and a pharmaceutically acceptable carrier into the distal colon of the subject.
• an enteric neuropathy e.g., HSCR or intestinal hypoganglionosis
• the present disclosure also provides the use of a pharmaceutical composition
• a pharmaceutical composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), wherein the composition is for administration into the distal colon of the subject.
• enteric neuropathy e.g., HSCR or intestinal hypoganglionosis
• the present disclosure also provides the use of a pharmaceutical composition
• a pharmaceutical composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier for restoring distal colon motility in a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), wherein the composition is for administration into the distal colon of the subject.
• enteric neuropathy e.g., HSCR or intestinal hypoganglionosis
• the present disclosure also provides the use of a pharmaceutical composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier for the manufacture of a medicament for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), wherein the medicament is for administration into the distal colon of the subject.
• an enteric neuropathy e.g., HSCR or intestinal hypoganglionosis
• the present disclosure also provides the use of a pharmaceutical composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier for the manufacture of a medicament for restoring distal colon motility in a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), wherein the medicament is for administration into the distal colon of the subject.
• an enteric neuropathy e.g., HSCR or intestinal hypoganglionosis
• the present disclosure also provides a pharmaceutical composition for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), the composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier, and wherein the pharmaceutical composition is for administration into the distal colon of the subject.
• an enteric neuropathy e.g., HSCR or intestinal hypoganglionosis
• the present disclosure also provides a pharmaceutical composition for restoring distal colon motility in a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), the composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier, and wherein the pharmaceutical composition is for administration into the distal colon of the subject.
• an enteric neuropathy e.g., HSCR or intestinal hypoganglionosis
• the composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier, and wherein the pharmaceutical composition is for administration into the distal colon of the subject.
• distal colon refers to the last three portions of the colon, namely the descending colon, the sigmoid colon and the rectum.
• the pharmaceutical composition is administered or is for administration into the rectum and/or the sigmoid colon.
• the pharmaceutical composition is administered or is for administration into the rectosigmoid region, which comprises the last part of the sigmoid colon and the beginning of the rectum.
• the pharmaceutical composition may be administered directly into the distal colon, or may be administered at a site away from the distal colon but using suitable means to provide delivery of the pharmaceutical composition (and more specifically of the human GDNF polypeptide) into the distal colon.
• the pharmaceutical composition may comprise a coating that is specifically degraded under the conditions (e.g., pH, enzymatic environment, bacterial environment, etc.) of the distal colon, and thus pharmaceutical composition may be administered in another region of the gastrointestinal system but the human GDNF polypeptide will only be released once the pharmaceutical composition reaches the colon, and more specifically the distal colon.
• Conditions e.g., pH, enzymatic environment, bacterial environment, etc.
• Approaches for colon specific drug delivery are well known in the art (see, e.g., Philip et al., Oman Med J. 2010 Apr; 25(2): 79-87; Lee et al., Pharmaceutics.
• pH-dependent systems e.g., using pH-dependent polymers
• receptor-mediated systems e.g., using pH-dependent polymers
• magnetically-driven systems e.g., magnetically-driven systems
• delayed or time-dependent systems e.g., microbially triggered drug delivery systems
• microbially triggered drug delivery systems e.g., comprising sugar-based polymers that may be degraded by enzymes produced by the colon microflora such as glucoronidase, xylosidase, arabinosidase, galactosidase), pressure controlled colonic delivery capsule (drug release induced by the higher pressures encountered in the colon), osmotic controlled drug delivery, as well as any combinations of these approaches (e.g., colon targeted delivery system (CODESTM) using a combined approach of pH dependent and microbially triggered drug delivery).
• CODESTM colon targeted delivery system
• enteric neuropathy refers to a disease associated with abnormalities in the ENS, including abnormal development of the ENS, e.g., abnormal number of neurons (hypoganglionosis, aganglionosis) and/or abnormal differentiation of neurons.
• enteric neuropathies include enteric dysganglionoses such as HSCR and intestinal hypoganglionosis.
• the enteric neuropathy is HSCR.
• the enteric neuropathy is intestinal hypoganglionosis.
• the expression “inducing enteric neurogenesis” as used herein refers to an increase in the production of enteric neurons and/or enteric glial cells relative to prior to treatment with the composition comprising a human GDNF polypeptide.
• the enteric nervous system comprises various types of neurones including enteric primary afferent neurons (EPANs), excitatory circular muscle motorneurons, inhibitory circular muscle motorneurons, longitudinal muscle motorneurons, ascending interneurons, descending interneurons, secretomotor and vasomotor neurons, and intestinofugal neurons, as well as enteric glial cells (EGCs) that provide structural support to neurons and contribute to neuronal maintenance, survival, and function (Costa et al., Gut 2000;(Suppl IV) 47: iv15-iv19; De Giorgio et al., American Journal of Physiology- Gastrointestinal and Liver Physiology, Vol. 303, No. 8: G887-G893, 2012).
• GECs enteric glial
• the production of one or more of these cell types may be induced by the administration/use of the composition comprising a human GDNF polypeptide.
• the production of EGCs preferably Sox10-expressing EGCs, is induced by the administration/use of the composition comprising a human GDNF polypeptide.
• the administration/use of the composition comprising a human GDNF polypeptide restores the enteric neurons/glial cell ratio in the colon (e.g., distal colon) of the patient.
• the enteric neurons/glial cell ratio in the colon (e.g., distal colon) of the patient is at least 0.5, e.g., between 0.5 and 1.5.
• the administration/use of the composition comprising a human GDNF polypeptide restores the proportions of nitrergic (nNOS + ) and cholinergic (ChAT + ) neurons in the colon (e.g., distal colon) of the patient.
• the administration/use of the composition comprising a human GDNF polypeptide reduces the infiltration of inflammatory or immune cells (e.g., neutrophils) in the colon (e.g., distal colon). In another embodiment, the administration/use of the composition comprising a human GDNF polypeptide restores (partly or completely) the proportions of immune cells in the colon (e.g., distal colon).
• inflammatory or immune cells e.g., neutrophils
• the administration/use of the composition comprising a human GDNF polypeptide restores (partly or completely) the proportions of immune cells in the colon (e.g., distal colon).
• human GDNF polypeptide refers to the native mature human GDNF protein, or to functional variants or fragments thereof that retain a biological activity of the native mature human GDNF protein, e.g., the ability to bind to a GDNF receptor (particularly the "rearranged during transfection” (RET) proto-oncogene and/or the Neural Cell Adhesion Molecule (NCAM) receptor) and trigger a signal in a cell expressing a GDNF receptor (e.g., RET and/or NCAM).
• RET rearranged during transfection
• NCAM Neural Cell Adhesion Molecule
• the amino acid sequence of native human GDNF protein is depicted in FIG.
• the GDNF precursor protein is processed to a mature secreted form that exists as a homodimer.
• Each GDNF monomer contains seven conserved cysteine residues, including Cys-101 , which is used for inter-chain disulfide bridging, and others that are involved in the intramolecular ring formation known as the cysteine-knot configuration.
• the human GDNF polypeptide is a recombinant human GDNF polypeptide.
• the term “recombinant” when made in reference to a protein or a polypeptide refers to a protein or polypeptide molecule that is not isolated from a natural source (e.g., biological sample), e.g., which is expressed from a recombinant nucleic acid construct created by means of molecular biological techniques. Referring to a nucleic acid construct as “recombinant” therefore indicates that the nucleic acid molecule has been manipulated using genetic engineering, i.e. by human intervention. Recombinant nucleic acid constructs may for example be introduced into a host cell by transformation (e.g., transduction or transfection).
• Functional variants or fragments of native mature human GDNF protein may include one or more amino acid substitutions, deletions and/or additions relative to the native mature human GDNF protein, and may have a biological activity that is lower, equivalent or higher than that of the native mature human GDNF protein.
• the functional variant or fragment has an activity that is equivalent (e.g., between 90% to 110%) or higher (e.g., more than 110%) to that of the native mature human GDNF protein.
• the variant comprises one or more conservative substitutions.
• Conservative amino acid substitutions are known in the art, and include amino acid substitutions in which one amino acid having certain physical and or chemical properties is exchanged for another amino acid that has the same chemical or physical properties.
• the conservative amino acid substitution can be an acidic amino acid substituted for another acidic amino acid (e.g., Asp to Glu or vice-versa), an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, lie, Leu, Met, Phe, Pro, Trp, Val, etc.), a basic amino acid substituted for another basic amino acid (Lys, Arg, etc.), an amino acid with a polar side chain substituted for another amino acid with a polar side chain (Asn, Cys, Gin, Ser, Thr, Tyr, etc.).
• an amino acid with a polar side chain substituted for another amino acid with a nonpolar side chain e.g., Ala, Gly, Val, lie, Leu, Met, Phe, Pro, Trp, Val, etc.
• a basic amino acid substituted for another basic amino acid e.g., Ala, Gly, Val, lie, Leu, Met, P
• the variants can comprise the amino acid sequence of the native GDNF protein or polypeptide with at least one nonconservative amino acid substitution.
• the non-conservative amino acid substitution(s) enhance(s) the activity of the variant relative to that of the native mature human GDNF protein.
• the human GDNF polypeptide has the ability to bind to the RET receptor.
• the human GDNF polypeptide has the ability to bind to the NCAM receptor.
• the human GDNF polypeptide comprises at least 10, 15 or 20 amino acids (e.g ., contiguous amino acids) from the mature human native GDNF protein.
• the human GDNF polypeptide comprises the sequence ETTYDKILKNLSRNR (gliafin, SEQ ID NO:3), which corresponds to residues 153-167 of SEQ ID NO: 1 and is the putative binding domain of human GDNF to the NCAM receptor (see, Nielsen et a!., J Neurosci. 2009 Sep 9; 29(36): 11360-11376).
• the human GDNF polypeptide comprises at least 25, 30, 35, 40, 45, 50, 60, 70, 80, 90 or 100 amino acids (e.g., contiguous amino acids) from the mature human native GDNF protein.
• the human GDNF polypeptide comprises an amino acid sequence that is at least 50%, 60% or 70% identical to the sequence of residues 78-211 depicted in FIG. 178A (SEQ ID NO:1). In another embodiment, the human GDNF polypeptide comprises an amino acid sequence that is at least 80% identical to the sequence of residues 78-211 depicted in FIG. 17A (SEQ ID NO:1). In another embodiment, the human GDNF polypeptide comprises an amino acid sequence that is at least 85% identical to the sequence of residues 78-211 depicted in FIG. 17A (SEQ ID NO:1). In another embodiment, the human GDNF polypeptide comprises an amino acid sequence that is at least 90% identical to the sequence of residues 78-211 depicted in FIG.
• the human GDNF polypeptide comprises an amino acid sequence that is at least 95% identical to the sequence of residues 78-211 depicted in FIG. 17A (SEQ ID NO:1). In another embodiment, the human GDNF polypeptide comprises an amino acid sequence that is at least 98% identical to the sequence of residues 78-211 depicted in FIG. 17A (SEQ ID NO:1). In another embodiment, the human GDNF polypeptide comprises an amino acid sequence that is at least 99% identical to the sequence of residues 78-211 depicted in FIG. 17A (SEQ ID NO:1). In another embodiment, the human GDNF polypeptide comprises or consists of the sequence of residues 78-211 depicted in FIG.
• Identity refers to sequence identity between two polypeptides. Identity can be determined by comparing each position in the aligned sequences. Methods of determining percent identity are known in the art, and several tools and programs are available to align amino acid sequences and determine a percentage of identity including EMBOSS Needle, ClustalW, SIM, DIALIGN, etc. As used herein, a given percentage of identity with respect to a specified subject sequence, or a specified portion thereof, may be defined as the percentage of amino acids in the candidate derivative sequence identical with the amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the Smith Waterman algorithm (Smith & Waterman, J. Mol.
• Covalent modifications of the human GDNF polypeptide are included within the scope of this disclosure.
• the native glycosylation pattern of the human GDNF polypeptide may be modified (Beck et al., Curr. Pharm. Biotechnol. 9: 482-501 , 2008; Walsh, Drug Discov. Today 15: 773-780, 2010), and linking the human GDNF polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos.
• PEG polyethylene glycol
• polypropylene glycol polypropylene glycol
• polyoxyalkylenes polyoxyalkylenes
• the human GDNF polypeptide may comprise one or more modifications that confer additional biological properties to the polypeptide such as protease resistance, plasma protein binding, increased plasma half-life, tissue or intracellular penetration, etc.
• modifications include, for example, covalent attachment of molecules/moiety to the polypeptide such as fatty acids (e.g., C 6 -Ci 8 ), attachment of proteins such as albumin (see, e.g., U.S. Patent No.
• the human GDNF polypeptide may also be conjugated to moieties to induce its multimerization or oligomerization (e.g., tetramerization), for example by fusing the human GDNF polypeptide to an oligomerization domain orto a molecule that may be oligomerized (e.g., biotin that may bind to 4 binding sites on streptavidin).
• the human GDNF polypeptide may also be conjugated to moieties that will target the GDNF polypeptide to the distal colon or to specific cells of the distal colon (e.g., Schwann cells and/or precursor thereof), for example using an antibody, antibody fragment or ligand that binds to a marker present on cells from the distal colon.
• moieties that will target the GDNF polypeptide to the distal colon or to specific cells of the distal colon (e.g., Schwann cells and/or precursor thereof), for example using an antibody, antibody fragment or ligand that binds to a marker present on cells from the distal colon.
• the human GDNF polypeptide can also be conjugated to one or more therapeutic or active agents (e.g., to a drug, orto another polypeptide to form a fusion polypeptide).
• therapeutic or active agents e.g., to a drug, orto another polypeptide to form a fusion polypeptide.
• Any method known in the art for conjugating the human GDNF polypeptide to another moiety e.g., active agent
• the effective dose of recombinant GDNF polypeptide administered or for administration to the human subject corresponds to a dose of about 5 pg to about 20 pg in a mouse pup, which is the range shown to be effective in the studies described herein.
• a 10 pi enema comprising a recombinant GDNF solution was administered to mouse pups. 10 pi is estimated to correspond to the volume necessary to fill the distal colon and rectum of the pups.
• administration of 5 pg GDNF in mice is achieved by administering 10 pi of a 0.5 pg/pl GDNF solution
• administration of 20 pg GDNF in mice is achieved by administering 10 mI of a 2.0 pg/mI GDNF solution.
• the volume required to fill the distal colon and rectum of a human baby may be estimated using the formula: 10ml x weight of the baby (in kg). Accordingly, a dose of 5 mg GDNF in mice corresponds to about 5 mg per kg in a human baby, and a dose of 20 pg GDNF in mice corresponds to about 20 mg per kg in a human baby.
• the effective dose of recombinant GDNF polypeptide administered or for administration to the human subject is about 5 mg to about 20 mg per kg, preferably about 10 mg to about 15 mg per kg.
• the recombinant GDNF polypeptide is administered or is for administration through a 0.5 mg/ml to 2 mg/ml composition (solution or gel).
• Formulations for rectal/distal colon administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax, or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the appropriate body cavity and release the composition comprising GDNF. More recently, liquid suppositories have been developed.
• Liquid suppositories typically contain thermosensitive and/or mucoadhesive polymers such as poloxamers, Carbopol ® (crosslinked polyacrylic acid polymers), sodium alginate, polycarbophil, hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, and methylcellulose.
• thermosensitive and/or mucoadhesive polymers such as poloxamers, Carbopol ® (crosslinked polyacrylic acid polymers), sodium alginate, polycarbophil, hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, and methylcellulose.
• Formulations for rectal/distal colon administration may also be presented as an enema, a liquid-drug solution, suspension or emulsion that is injected into the rectum and the distal colon.
• the liquid in which the GDNF polypeptide is diluted may be water or a saline solution, for example.
• Formulations for rectal/distal colon administration may also be in the form of a rectal foam or gel.
• Rectal gels are semi-solid formulations that contain a solvent trapped within a polymer network to create a viscous consistency. Viscosity of the gel can be modified by the addition of co-solvents (e.g., glycerin and propylene glycol) and electrolytes.
• Foams comprise a hydrophilic liquid continuous phase containing a foaming agent and a gaseous dispersion phase distributed throughout. Following rectal administration, they transition from a foam state to a liquid or semi-solid state on the mucosal surface.
• Foaming agents are typically amphiphilic substances that are important for foam generation and stabilization.
• the molecules contain hydrophilic components that are soluble in the aqueous phase and hydrophobic components that form micelles to minimize contact with the aqueous phase.
• Administration into the rectum/distal colon may be performed using currently available endoscopes or specialized catheters designed for rectal administration or injection into the distal colon wall of medications and liquids, which may be placed safely and remain comfortably in the rectum for repeated use.
• composition comprising GDNF polypeptide may be administered according to any suitable dosage regimen, for example four times-a-day, twice-a-day, once-a-day, twice-a-week, once-a-week, etc.
• the treatment may be performed for any suitable period of time to achieve the desired effect, for example for 1 week, 2 weeks, 3 weeks or more.
• the above-mentioned treatment comprises the use/administration of more than one (i.e. a combination of) active/therapeutic agent, one of which being the above- mentioned pharmaceutical composition comprising a GDNF polypeptide.
• the combination of therapeutic agents and/or compositions may be administered or co-administered (e.g., consecutively, simultaneously, at different times) in any conventional dosage form.
• Co administration in the context of the present disclosure refers to the use of more than one therapy in the course of a coordinated treatment to achieve an improved clinical outcome.
• the pharmaceutical composition comprising a GDNF polypeptide described herein may be used in combination with other therapies or drugs, for example analgesics or anti-inflammatory agents.
• the pharmaceutical composition comprising a GDNF polypeptide described herein may also be used in combination with an agent that stimulate ENS progenitor proliferation, such as a neurotrophic molecule.
• the above-mentioned treatment with a composition comprising GDNF polypeptide may be performed in combination with surgery (e.g., pull-through surgery of the Swenson, Soave or Duhamel type).
• surgery e.g., pull-through surgery of the Swenson, Soave or Duhamel type.
• clinicians often recommend a trial of daily enema treatments prior to surgery. Addition of recombinant GDNF to the enema might increase the likelihood that children with HSCR responded well to pre-operative enema therapy.
• the above-mentioned treatment with a composition comprising GDNF polypeptide is performed prior to pull-through surgery. Saline enemas are also commonly used in children with HSCR after pull-through surgery.
• Post-surgical problems in HSCR patients are believed to be due at least in part to hypoganglionosis in retained distal bowel, the so-called “transition zone”.
• addition of recombinant GDNF to the enema may be useful to correct the hypoganglionosis in retained distal bowel after surgery.
• the above-mentioned treatment with a composition comprising GDNF polypeptide is performed after pull-through surgery.
• the above-mentioned treatment with a composition comprising GDNF polypeptide is performed in combination with ENS stem cell-based therapies, which are being considered for the treatment of HSCR.
• GDNF may be a useful adjunct to these therapies to promote engraftment.
• HSCR is clinically subdivided into short-segment (S-HSCR) and long-segment forms (L- HSCR).
• S-HSCR which occurs in >80% of cases, means the ENS is absent from rectum and sigmoid colon.
• L-HSCR means longer regions of distal bowel are aganglionic.
• the method/use described herein is for the treatment of a human patient suffering from S-HSCR or L-HSCR. In an embodiment, the method/use described herein is for the treatment of a human patient suffering from S-HSCR. In an embodiment, the method/use described herein is for the treatment of a human patient suffering from L-HSCR.
• the HSCR patient may be an adult patient or pediatric patient.
• the HSCR patient is a pediatric patient, preferably a patient that is less than 5, 4, 3 or 2 year-old, more preferably a patient that is less than 1 year-old or less than 6 month-old.
• the patient is a male.
• HSCR has been associated with mutations in RET, EDNRB, SOX10, PHOX2B, and ZFHX1B, as well as with Down syndrome or Trisomy 21 (Collagen Vl-associated HSCR). There is also a significant sex difference with male to female ratio as high as 5 to 1.
• the HSCR is Collagen Vl-associated HSCR.
• the HSCR is EDNRB mutation-associated HSCR.
• the HSCR is male-biased HSCR.
• the HSCR is a RET mutation-associated HSCR, e.g., HSCR associated with a mutation that reduces RET expression and/or activity in cells from the distal colon.
• the mutation may be a mutation in RET or in a protein involved in RET signaling.
• the mutation is a mutation in the RET protein. Mutations in the RET gene on chromosome 10q11.2 have been shown to account for 50% of familial and 15-20% of sporadic cases of HSCR, most of which (-75%) were associated with L-HSCR.
• the HSCR is not a RET mutation-associated HSCR.
• mice lines used were R26 [Fioxedstop]YFP (Gt[ROSA]26SoF 1(E/FP)Cos ⁇ , provided by F. Costantini (Columbia University, USA) and maintained on an FVB/N background) (80).
• mutant mouse pups were identified at P3 via pigmentation- based genotyping.
• 10 pi enemas consisting of a 1 pg/pl solution of recombinant human mature GDNF (Peprotech cat. # 450-10) diluted in PBS were administered daily between P4 to P8.
• Clinical grade GDNF Medgenesis Therapeutix Inc., Canada
• 6XHis-tagged version 583 used for some experiments had similar efficiency.
• Enemas were administered using a 24-gauge gavage needle (Fine Science Tools, Canada) attached to a micropipette. The head of the gavage needle was introduced in the rectum just beyond the anus (pre-lubricated with VaselineTM), and enemas were injected over the course of a few seconds. Pups were then placed back with their mother, and either sacrificed at P20 for tissue analysis or checked daily to track survival.
• mouse pups received 10 pi intraperitoneal injections of a 10mM EdU solution (ThermoFisher Scientific, Cat. # C10337) once a day during the 5-day (P4 to P8) GDNF enema treatment.
• Tissue labelling and imaging For immunofluorescence staining, whole microdissected tissues were permeabilized for 2 hours in blocking solution (10% FBS and 1% TritonTM X-100, in PBS) before being sequentially incubated with specific primary (at 4°C overnight) and relevant secondary (at room temperature for 2 hours) antibodies, both diluted in blocking solution that was also used to wash tissues between all steps. All antibodies and dilution factors are listed in Table 1. EdU was detected using the Invitrogen Click-iT EdU Imaging Kit (ThermoFisher Scientific, Cat. # C 10337) in accordance with the manufacturer’s instructions. For histological analyses, cross- sections of full-thickness bowel tissues were stained with hematoxylin and eosin (H&E) as previously described (83).
• H&E hematoxylin and eosin
• Table 1 List of primary antibodies and dilution factors used for immunofluorescence
• N-nitro-L-arginine methyl ester (L-NAME; Sigma, Cat. # N5751) and atropine (Sigma, Cat. # A01132) were added to Krebs solution at a final concentration of 0.5 pM and 1 pM, respectively.
• the area under the curve (AUC) was measured during each EFS-induced response, and data were expressed in AAUC (corresponding to the difference between the AUC measured 20s after stimulation minus the AUC measured 20s before stimulation).
• mice were sacrificed at P20 and their feces were directly collected from the colon (3 fecal pellets per mouse). Bacterial DNA was then extracted using the QIAamp® Fast DNA Stool Mini Kit (QIAGEN, Cat. # 51604), and the V5-V6 region of the 76S rRNA gene was PCR amplified with a collection of previously described barcoded primers (84).
• Raw sequences generated with an lllumina MiSeq sequencer were paired and processed using the MOTHUR pipeline (85), and the BIOM package (86) was subsequently used to transfer biom files into R (87) for generating graphs of relative taxa abundance and beta diversity.
• each petri dish was placed in a microscope incubation chamber (Okolab) for 10 hours under the same culture conditions, and image stacks (250 pm-thick) of RFP-labelled extrinsic nerves and SCPs were acquired every 10 min, using a 20X objective on a Nikon A1R confocal unit as previously described (39).
• Strips of living muscles were then prepared as described above and cut in smaller pieces of 0.5 cm X 0.5 cm. At least one of these small pieces was immediately fixed and kept aside for validation of aganglionosis via immunofluorescence, while the others were cultured for 96h as described above for inducing neurogenesis in mouse tissues. Samples from two patients (aged of 86 and 1638 days at the time of surgery) were in addition cultured for 7 days, under the same conditions. At the end of culture period, all tissues were fixed with PFA and processed for immunofluorescence and EdU labelling.
• Example 2 GDNF enemas rescue aganglionosis in three mouse models of short-segment
• the enema volume necessary to fill whole colon, concentration of GDNF homodimer (30 kDa), treatment time window, as well as duration and frequency of therapy were first determined with Hol Tg/Tg pups (FIGs. 1A-D). It was observed that administration of 100 pg of GDNF reduces survival relative to saline control (FIG. 1C), suggesting that such dose is toxic or worsens the disease. Administration of 1 pg or 25 pg of GDNF had no significant effect on survival, and 10 or 15 pg were shown to be optimal to improve survival. Remarkably, the selected treatment (i.e.
• distal colon from GDNF-treated Hol Tg/Tg animals had numerous HuC/D + neurons and SOX10 + glia organized into ganglia between circular and longitudinal smooth muscles (FIG. 2D). These myenteric ganglia were primarily adjacent to extrinsic nerve fibers with SOX10 + cells.
• Tuj1 labeling further revealed that GDNF-induced neural ganglia formed interconnected networks in both myenteric and submucosal plexuses (FIG. 3). Quantification of myenteric neuron density in whole colon of Hol Tg/Tg and male TashT Tg/Tg mice showed GDNF effects are most prominent in distal colon (i.e. final 3 cm), with minor effects in proximal colon (FIGs.
• FIG. 2D In the midcolon of GDNF-treated Hol Tg/rg mice, the increased neuron density (FIG. 2D) was mainly due to an enlargement of pre-existing myenteric ganglia, as evidenced by a higher proportion of large ganglia (i.e. >50 neurons) (FIG. 4A). In the most distal colon, where untreated Hol Tg/Tg mice are normally devoid of enteric neurons, GDNF-treated Hol Tg/Tg mice had an average neuron density that was 40% that of WT mice (5.2 ⁇ 2.2 % vs 13.1 ⁇ 3.6 %) (FIG. 2D).
• EdU labeling confirmed that GDNF induced proliferation of neuron and glia progenitors during the 5-day treatment from P4 to P8.
• Immunofluorescent staining of P20 Hol T9/T9 colon from mice that received daily EdU injections during the GDNF treatment period revealed many EdU + HuC/D + (presumptive neurons) and EdU + SOX10 + (presumptive glia or neuron/glia progenitors) in both myenteric and submucosal ganglia (FIGs. 2E-F and 5A-C). The percentage of EdU + cells was quite variable from ganglion to ganglion (FIG. 5C).
• Example 3 GDNF-induced ENS is morphologically and functionally similar to WT
• GDNF-induced ENS in the distal colon resembles WT at P20.
• TFT thyroid factor hydroxylase
• CalR + calretinin
• VIP + vasoactive intestinal peptide
• SubP + substance P excitatory motor neurons
• GDNF treatment also corrected the imbalance of nitrergic (increased) and cholinergic (decreased) neuron subtypes that is observed upstream of the aganglionic segment in both HSCR mouse models and human patients (38, 48-51).
• Colon motility was also evaluated ex vivo using strips of distal colon muscularis externa from P20 animals attached to force transducers in an organ bath. This system allows electric field stimulation-induced contractions of WT colon muscles to be slightly increased by inhibition of nitric oxide synthase with L-NAME (nitro-L-arginine methyl ester), which can then be robustly counteracted by inhibition of cholinergic signaling with atropine (muscarinic receptor antagonist). Similar to in vivo data, colon muscle strips from GDNF-treated HoF 9/T 9 mice displayed one of two distinct response patterns. Some GDNF-treated HoG 9/G9 colon responses were similar to WT (4/7 mice) while others responded similar to untreated Hol Tg/rg (3/7 mice) (FIG.
• Hol Tg/rg mouse colon had thicker smooth muscles and more neutrophils than WT mice, but GDNF-treated Hol Tg/Tg mouse colon was similar to WT (FIGs. 6G-I and 9A-B).
• stool microbiome profiling demonstrated dysbiosis in P20 Hol Tg/Tg mouse colon, but average abundance of several bacterial genera in Hol Tg/Tg mouse colon were indistinguishable from WT after GDNF treatment (e.g., Desulfovibrio, Escherichia, Helicobater, Mucispirillum, Oscillospira, Parabacteroides, and Sutterella) (FIG. 6J).
• Example 4 SCPs within extrinsic nerves are a target of GDNF in aganglionic colon
• GDNF distribution in bowel was first evaluated via Western blot, taking advantage of size differences between recombinant (15 kDa) and endogenous (20 kDa, glycosylated) GDNF proteins in SDS-PAGE gels. Consistent with increased epithelial permeability in distal colon of Hol Tg/Tg mice (FIG. 6F), recombinant GDNF protein was detected in GDNF-treated Hol Tg/Tg distal colon at P8, but not in proximal colon (FIG. 10A).
• SCPs were previously reported to contribute 20% of colonic neurons in a mixed C57BL/6- 129Sv genetic background at 1 month of age (29), they were found to contribute only 5-7% of myenteric neurons in a pure FVB/N genetic background at P20, and this contribution increased to 10-11% in the presence of the homozygous Holstein mutation (FIGs. 13A,B) ⁇
• SCP-derived (YFP + ) cells made up 34% of distal colonic neurons in GDNF-treated Hol T9/T9 Dhh- Cre Je,+ ⁇ R26 YFP,+ animals (FIGs. 10G,H).
• Example 5 GDNF can induce new neurons in human aganglionic colon ex vivo
• GDNF could induce neurogenesis in aganglionic human colon muscle from children who had Swenson pull-through surgery to resect aganglionic distal bowel.
• the cohort consisted of 12 children. Epidemiologic characteristics were typical of HSCR (i.e., mostly sporadic, male-biased, short-segment) (Table 2). Patients who underwent Soave surgery were not enrolled because muscularis externa is not resected from the most distal colon with this approach. For each subject, full-thickness resected aganglionic colon was collected on the day of surgery and immediately micro-dissected to remove mucosal and submucosal layers.
• Remaining muscularis externa was cut into smaller pieces and cultured with or without GDNF. Exposure to GDNF for 96h markedly increased the proportion of EdlT SCPs in 9/9 human tissues where EdU was added to media (FIG. 14D,E). Most importantly, new neurons expressing HuC/D, bIII-T ubulin (Tuj1), RET, PGP9.5 and PHOX2B were also detected in three HSCR explants (FIGs. 14F,G and 16). These three explants were from the youngest children of our cohort (28 to 44 days old) (FIG. 14G and Table 2). Two of these young children had sporadic HSCR with unknown genetic causes.
• the third child had a MEN2A syndrome-associated RET mutation (Table 2).
• Table 2 For older children, it was tested whether longer GDNF treatment might be beneficial.
• Table 2 Overview of HSCR colon samples used for ex vivo preclinical testing of GDNF therapy.
• Multi-color flow cytometry analysis shows that the abnormal proportions of immune cells observed in the colon of untreated /-/o/ Tg/Tg mice become generally normalized back to WT immune cell proportions upon GDNF treatment.
• density plots shows either a complete (B cells, CD73 + T cells, CD44 + CD62L + T cells, RORy + T cells, CX3CR1 + MHC-II + macrophages) or at least partial (CD4 + T cells, CD39 + T cells, CD25 + T cells, Ly-6C + CD64 + monocytes, F4-80 + MHC-N + macrophages, CD11b + CD103 _ macrophages) rescue.
• Table 3 The results are summarized in Table 3.
• Gdnf is mitogenic, neurotrophic, and chemoattractive to enteric neural crest cells in the embryonic colon. Dev Dyn 240, 1402-1411 (2011).
• GDNF is a chemoattractant for enteric neural cells. Dev Biol 229, 503- 516 (2001).
• Glial cell line-derived neurotrophic factor alters axon schwann cell units and promotes myelination in unmyelinated nerve fibers. J Neurosci 23, 561-567 (2003).
• NCAM neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Ce// 113, 867-879 (2003).
• NCAM neural cell adhesion molecule
• Neural crest stem cells persist in the adult gut but undergo changes in self-renewal, neuronal subtype potential, and factor responsiveness. Neuron 35, 657-669 (2002).
• RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons. Development 128, 3963-3974 (2001).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Psychology (AREA)
• Zoology (AREA)
• Immunology (AREA)
• Gastroenterology & Hepatology (AREA)
• Surgery (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=76476522

Family Applications (1)

Country Status (6)

Families Citing this family (1)

Citations (11)

Family Cites Families (2)

• 2020
  • 2020-12-18 CA CA3162011A patent/CA3162011A1/en active Pending
  • 2020-12-18 ES ES20901160T patent/ES3036928T3/es active Active
  • 2020-12-18 JP JP2022538283A patent/JP7665215B2/ja active Active
  • 2020-12-18 WO PCT/CA2020/051746 patent/WO2021119827A1/en not_active Ceased
  • 2020-12-18 EP EP20901160.0A patent/EP4076499B1/en active Active
  • 2020-12-18 US US17/757,570 patent/US20230022970A1/en active Pending

Patent Citations (11)

Non-Patent Citations (111)

Also Published As

Similar Documents

Legal Events